GlycoEra: applying glycoengineering techniques to therapeutics development

As glycoengineering technology developed at Zurich-based LimmaTech began to show promise in the generation of both vaccines and therapeutics, the company decided to spin out GlycoEra for the latter application, with VCs supplying the bulk of its new series A round.

GlycoEra AG said Friday it had raised CHF45 million ($49.1 million) to advance a platform with which it intends to develop therapeutics based on glycan-mediated biology. Leading the round were 5AM Ventures, Roche Venture Fund and Sofinnova Partners; LimmaTech Biologics AG also participated...